Figure 10.

6MMPr synergistically enhances anti-SARS-CoV-2 activity of favipiravir. Vero-E6 cells were inoculated with SARS-CoV-2 at MOI of 0.01 for 72 hpi in the presence of 0, 31, 62.5, 125, 250, and 500 µM of favipiravir (FAV) (A), T-1105 (C), and T-1106 (E). The percent of infected cells was calculated by immunostaining of viral nucleoprotein and used to build infectious dose-response curves. EC₅₀ values are indicated for favipiravir and T-1105 alone and in combination with 6MMPr. The 3D plots in (B,D,F) indicate synergistic antiviral effect or lack thereof for each combination. (G) Total number of cells quantified by DAPI staining from panel (A,C,E) was used to calculate % cell viability for FAV, T-1105, and T-1106 alone or in combination with 6MMPr. The graphs depict the mean ± SEM of two independent experiments with three biological replicates. Total volume of synergy = TVS. All TVS calculated at 99.9% confidence interval. Dotted black line indicates 50%.